

1 **Reduced *Bacille Calmette-Guérin*-specific IgG titres among babies born to mothers with**
2 **Active Tuberculosis Disease in Uganda**

3 **Authors**

4 Diana Sitenda^{*1,2,3}, Phillip Ssekamatte^{1,2,7}, Rose Nakavuma², Andrew Peter Kyazze^{2,8}, Felix
5 Bongomin⁴, Joseph Baluku⁷, Rose Nabatanzi¹, Davis Kibirige^{2,6}, Annette Nakimuli⁵, Stephen
6 Cose⁷, Irene Andia-Biraro^{2,7,8}.

7 **Affiliations**

- 8 1. Department of Immunology and Molecular Biology, School of Biomedical Sciences,
9 College of Health Sciences, Makerere University, Kampala, Uganda.
- 10 2. Tuberculosis and comorbidities research consortium, Kampala, Uganda.
- 11 3. Health Professions Education and Training for Strengthening the Health System and
12 Services, Kampala, Uganda.
- 13 4. Department of Medical Microbiology and Immunology, Gulu University (GU), Gulu,
14 Uganda.
- 15 5. Department of Obstetrics and Gynaecology, School of Medicine, College of Health
16 Sciences, Makerere University, Kampala, Uganda.
- 17 6. Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala, Uganda
- 18 7. Medical Research Council/ Uganda Virus Research Institute and London School of
19 Hygiene and Tropical Medicine, Entebbe, Uganda.
- 20 8. Department of Internal Medicine, School of Medicine, College of Health Sciences,
21 Makerere University, Kampala, Uganda.

22 ***Correspondence**

23 Corresponding Author: Ms Diana Sitenda

24 Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere
25 University, Kampala, Uganda. Email: dianasitenda@gmail.com

26 **Abstract (284)**

27 **Background:** Babies born to mothers with active tuberculosis disease (ATB) are at risk of poor
28 clinical outcomes such as low birth weight and perinatal mortality. However, little is known
29 about the influence of maternal ATB exposure on their vaccine responses during infancy. The
30 study aimed to explore how maternal ATB affects infants' vaccine responses, hypothesising
31 reduced responses to BCG and other infant vaccines.

32 **Methods:** This was a case-control study with a longitudinal component of babies born to
33 mothers with bacteriologically confirmed ATB (cases) and babies born to mothers without ATB
34 (controls) carried out between September 2021 and June 2022. Quantitative BCG, diphtheria,
35 tetanus, and measles-specific IgG ELISA assays were performed on infant plasma harvested
36 from lithium-heparin blood collected on first encounter after birth (0), at 3, 6, and 9 months. We
37 used prism v10.1.2, Mixed-effects modelling, and Tukey's multiple comparison testing to
38 determine mean differences (MD) between the cases and controls at all time points.

39 **Results:** Infants cases had reduced IgG titres to BCG at baseline compared to the controls
40 ($p=0.04$), with a mean of 125.8/141.1 IU/mL, respectively. This difference was, however, not
41 sustained at the other time points. Similarly, we demonstrated strong trends of reduced responses
42 to tetanus, diphtheria, and measles vaccines among infant cases at baseline and three-month time
43 points and weakly at months six and nine. The mean titres for tetanus at baseline and 3 months
44 for cases versus controls are 1.744/2.917 IU/mL and 1.716/2.344 IU/mL ($p<0.0001/0.018$),
45 respectively. The mean titres for diphtheria at 3 months were 0.022/0.075 IU/mL ($p=0.006$),
46 respectively.

47 **Conclusion:** We have demonstrated that maternal TB disease influences vaccine responses to
48 BCG and other infant vaccines. This has implications for increased risk of childhood TB and
49 other preventable diseases.

50 **Keywords:** Active tuberculosis, Mothers, Infants, Vaccine response.

51 **Funding:** This study was funded by the CRCK African Network (CAN) through the Francis
52 Crick Institute, United Kingdom, and Health Professions Education and Training for
53 Strengthening the Health System (HEPI-SHSSU) and Services in Uganda.

54 **Introduction**

55 The incidence of Tuberculosis (TB) disease among people aged below 30 years of age has
56 increased, hence increasing the number of childbearing women contracting the disease (1). The
57 TB burden in pregnancy globally is estimated to be 216,500 cases annually, with an increased
58 threefold risk of TB in this population (2). Mother-to-child transmission of TB may occur *in*
59 *utero* through hematogenous spread via the umbilical vein and aspiration or swallowing of
60 infected amniotic fluid (3, 4). TB disease in pregnancy leads to poor maternal and foetal
61 outcomes such as preterm birth, low birth weight (5), perinatal death, congenital anomalies,
62 small for gestational age, foetal distress, low Apgar scores, and rare congenital tuberculosis (6).
63 There is limited data on the immune responses to BCG and other vaccines of infants born to
64 mothers with active TB (ATB). Vaccination with BCG has been reported to be associated with
65 reduced infant mortality (7, 8) although it still remains unclear whether this is true to all
66 populations including babies born to mothers with active tuberculosis. A study by Lubyayi et al.,
67 2020 revealed that maternal Latent TB status does not affect the infants' response to BCG-
68 vaccine (9). On the other hand, Mawa et al., 2015 reported a decrease in PPD-specific responses
69 among infants born to mothers with latent tuberculosis infection at one week and six- weeks
70 following vaccination with BCG compared to the control group (10). Both studies explored the
71 impact of maternal latent TB on infant vaccine responses; however, in this study, we assessed
72 vaccine responses among infants born to active TB mothers and compared them with babies born
73 to TB-uninfected mothers. We found it important also to determine if exposure to TB disease
74 influenced the other infant vaccines to pave the way for possible public health-related
75 interventions, given that HIV alone has been implicated in causing a reduced response to
76 vaccines among infants (11).

77 This study determined the IgG titer responses to *Bacille Calmette-Guérin* (BCG), diphtheria,
78 tetanus, and measles vaccines in babies born to mothers with and without active TB disease at
79 baseline, three, six, and nine months of follow-up.

80 **Materials and Methods**

81 **Study design and population**

82 This was a case-control study with a longitudinal component. The study enrolled 35 women with
83 bacteriologically confirmed active TB as cases and 33 women without TB as controls matched
84 for maternal and gestational age from antenatal (ANC) and postnatal (PNC) clinics at three major
85 health facilities in Kampala, Uganda: Kasangati Health Center IV, Kisenyi Health Center IV, and
86 Kawempe National Referral Hospital. However, we considered 25 cases (babies born to mothers
87 with active tuberculosis disease) and 25 controls (babies born to mothers without active
88 tuberculosis disease) in our experiments, whose numbers also dropped in successive follow-up
89 months. Upon delivery, babies were assented to, enrolled in the study, and were followed up for
90 nine months. These babies donated up to six milliliters of blood in lithium-heparin tubes at
91 different time points, from which plasma was harvested and stored at -20°C in a freezer at the
92 Immunology laboratory of Makerere University College of Health Sciences (MakCHS). The
93 baseline visit (V0) marked the visit of the first encounter with infants aged less than a month
94 (cases, n=19 versus controls, n=15). The V1 marked a visit at three months (cases n=15 versus
95 controls n=14), V2 at six months (cases n=12 versus controls n=8), and V3 at 9 months (cases
96 n=8 versus controls n=4). Vaccine schedules included BCG at birth; pentavalent tetanus-
97 diphtheria-pertussis-hepatitis B-haemophilus influenzae type B (DPT-HEPB-HIB1) at 6, 10, 14
98 weeks; and measles at nine months.

99 **Laboratory methods**

100 Heparin blood was layered over Ficoll-paque in a ratio of 1:2 under a biosafety cabinet in a 15ml
101 Falcon tube. This was spun in a centrifuge at 1800rpm for 30 minutes to separate plasma and
102 PBMCs from red blood cells. Plasma was harvested using a pipette and was stored at -20°C

103 freezer. All assays for each vaccine were optimised to achieve a suitable dilution factor.
104 Archived available plasma samples were retrieved from a -20°C freezer and transferred to the
105 fridge at the temperature of 4°C overnight. They were then retrieved from the refrigerator and
106 thawed with the ELISA kits at room temperature (25°C) for 1 hour. Plasma samples were
107 vortexed to achieve uniform mixing, and 50µl were loaded into designated wells, in addition to
108 standards and blanks, of the 96-well ELISA plates. The human IgG-specific ELISA assays were
109 performed to determine plasma IgG titres of BCG, Diphtheria-Tetanus, and Measles vaccine
110 responses using the human BCG (Cat No. MBS702330), diphtheria (Cat No. MBS495632),
111 tetanus (Cat No. MBS9907877) and measles (Cat No. MBS283708) IgG ELISA kits following
112 the manufacturer's instructions. The absorbance at 450/620 nm was measured using the Gen 5
113 software version 2.71.2 for the ELISA reader (Synergy LX multimode reader). Detailed
114 procedures are available in the supplementary materials.

115 **Data analysis and management**

116 Optical densities (ODs) from the ELISAs were converted to concentrations using the Gen 5
117 software version 2.71.2 and then exported to Excel. Using Excel, the data was cleaned and
118 grouped as cases versus controls at baseline, 3, 6, and 9 months. Data was statistically analysed
119 in GraphPad Prism v9.5.1 using the Mixed model effect analysis with Tukey's multiple
120 comparisons test. Means, mean difference (MD), and standard error of difference (SE) for both
121 cases and controls were computed at all time points. A simple linear regression analysis was
122 performed on the relationship between birth weight, haemoglobin, and vaccine responses at all
123 time points. The Mann-Whitney U-test was used to determine statistical differences in baby
124 weights, age, and the mother's haemoglobin concentrations among both cases and controls. The

125 chi-square test was also used to determine statistical differences in the gender of babies, their
126 postnatal versus antenatal enrolments, and their maternal HIV status.

127 **Ethical considerations**

128 This study received ethical approval from the School of Medicine Research and Ethics
129 Committee (SOMREC reference number SOM 2020-11); the School of Biomedical Sciences
130 (SOBSREC reference number SBS-2022-226) at Makerere University; and the Uganda National
131 Council for Science and Technology (UNCST registration number HS1396ES). The mothers
132 provided written informed consent and assent for their babies to participate in the study.

133 **Results**

134 **Characteristics of the study participants**

135 Babies born to mothers with ATB had lower birth weights than those born to mothers without
136 ATB ($p=0.03$), as shown in Table 1. In addition, case mothers had lower haemoglobin
137 concentrations compared to controls. The median (g/dl) and IQR cases versus controls are 11.2
138 (10.0-11.9)/ 13.0 (10.7-13.8) ($p=0.033$). Other characteristics such as age, gender, maternal HIV
139 status, and postnatal versus antenatal babies were found to be similar for both cases and controls.

140 **BCG-specific IgG responses**

141 The IgG titres were determined in plasma samples of the case babies versus the control babies.
142 The samples were collected at V0, V1, V2, and V3, and the titres were compared at all time
143 points. The IgG titres were strongly decreased in cases versus controls ($p=0.032$) at V0. The
144 mean for cases versus controls (IU/mL), mean difference (MD) 95% confidence interval (CI), P-
145 value, and Standard Error (SE)] are shown in Table 2. This was followed by a gradual reduction

146 at the rest of the time points: 3, 6, and 9 months ($p=0.574/0.626/0.717$), respectively. These
147 differences were, however, not supported, as demonstrated in Figure 1 (A and B).

148 **IgG vaccine responses to other vaccines**

149 **Tetanus-specific IgG responses**

150 Baby cases had slightly lower IgG responses to tetanus at baseline compared to the controls
151 ($p<0.0001$)

152 and this was followed by a significant decrease at 3 months ($p=0.018$). The mean (IU/mL), mean
153 difference (MD), 95% confidence interval (CI), P-value, and Standard Error (SE) are shown in
154 Table 2. The trends showed a steep reduction in the responses among controls; however, the
155 tetanus titres among cases increased gently up to 9 months, slightly surpassing the controls
156 observed to fairly rebound at 9 months, as shown in Figure 2(A and B).

157 **Diphtheria-specific IgG responses**

158 Cases had strongly reduced IgG responses at 3 months of follow-up ($p=0.0059$) compared to
159 controls. The mean (IU/mL), mean difference (MD) 95% confidence interval (CI), P-value, and
160 Standard Error (SE) are shown in Table 2. A sharp increase followed this in titres, which peaked
161 at 6 months and then dropped at 9 months for controls. On the other hand, the responses for cases
162 are steadily maintained from baseline up to the end of follow-up, as shown in Figure 2(C and D).
163 At months 6 and 9, the p values were $p=0.8563$ and 0.8589 , respectively. No difference was
164 observed in the response to diphtheria at baseline ($p=0.392$).

165 **Measles-specific IgG responses**

166 The trends showed that cases had a slightly higher response at all time points than controls, with
167 the highest response shown at month 9. On the contrary, controls show waning titres between
168 months 6 and 9. At baseline, 3, 6, and 9 months, the p values were:

169 $p=0.7402/0.9339/0.4409/0.5155$, respectively. These differences were, however, not statistically
170 supported, as shown by Figure 2(E and F). The mean (IU/mL), mean difference (MD) 95%
171 confidence interval (CI), P-value, and Standard Error (SE) are shown in Table 2.

172 **Impact of birth weight on vaccine responses**

173 In this study, we further grouped cases and controls as either normal or low weights (kgs) based
174 on the World Health Organisation's guidelines, and babies with a weight lower than 2.5 kgs were
175 considered low weight. Normal weight ranged between 2.5 and 4.0 kgs. BCG and tetanus-
176 specific IgG titres for normal weight were lower among cases than controls. However, there was
177 no difference in diphtheria and measles vaccine responses between low and normal-weight
178 babies, as shown in Figure 3 (A, B, C, and D). A comparison of the vaccine responses to BCG,
179 tetanus, diphtheria, and measles vaccines and normal birthweight revealed that cases with normal
180 weight had low responses to BCG and tetanus vaccines. No differences were observed among
181 low-weight babies and measles and diphtheria responses. For normal weight (cases versus
182 controls), BCG, $p=0.007$; tetanus, $p=0.004$; DPT, $p=0.093$; measles, $p=0.055$. The regression
183 analysis also revealed that weight slightly affected BCG responses ($p=0.06$); however, this was
184 not statistically supported.

185 **Discussion**

186 Pregnancy modulates the immune response towards Th2-type response (12) increasing
187 susceptibility to intracellular pathogens, including TB (13). This study demonstrated that babies
188 born to mothers with ATB have reduced BCG-specific IgG titres at baseline. Maternal
189 tuberculosis disease potentially leads to the transfer of tuberculosis antigens to the foetus,
190 thereby resulting in an altered priming of the immune response (14). The observed reduced BCG
191 responses at baseline could, therefore, result in anergy induced by maternal antibodies; however,

192 this remains to be explored. The responses remained relatively stable over time. The results
193 further show that cases had slightly reduced responses at six months for BCG responses, unlike
194 for Measles. These results contradict what Edwards, 2015 (15) reported: measles vaccine
195 responses were reduced at six months, possibly due to passive maternal antibodies. On the other
196 hand, Nabunya et., 2020 reported that about 36% of infants are not breast fed beyond six months,
197 in Uganda (16). This implies that the transfer of the antibodies is reduced. Our results suggest the
198 insufficiency in responses to the BCG vaccine due to TB exposure. These findings show that
199 maternal TB may impair the infants' immune responses to the BCG vaccine. We suggest that
200 careful attention is taken to ensure that the infants exposed to TB can develop protective
201 immunity following vaccination to protect infants from early-life infections and deaths from
202 active TB.

203 In addition to BCG, the study reported a reduction in Diphtheria-specific IgG-specific titres
204 among cases at three months. Tetanus-specific IgG-specific vaccine responses were reduced at
205 baseline and three months among cases compared to the controls. This data highlights that
206 maternal TB disease indeed influences responses to vaccines among infants, and care should be
207 taken to ensure that these exposed infants achieve protective immunity following vaccination.
208 This will be aimed towards averting early-life infections and, consequently, potential infant
209 deaths attributable to active TB. DPT and measles responses are seen to rebound after three
210 months, shooting higher among cases than the controls at 6 and 9 months; however, the
211 differences in fluctuations are not significant. On the other hand, Tetanus responses for cases are
212 relatively stable over time, indicating minimal responsiveness to the vaccine.

213 The observed decrease in the IgG-specific diphtheria vaccine responses is consistent with
214 findings from similar studies. Abu-Raya et al., 2021 found lower IgG levels in children whose

215 mothers had received the Tdap vaccine (17). Due to the impact of TB in pregnancy, including
216 the low birth weight of babies, vaccination tends to be delayed. When administered, low vaccine
217 responses are more likely to occur (18) predisposing infants to developing vaccine-preventable
218 diseases and experiencing severe or fatal disease outcomes. It has also been demonstrated that
219 maternal *Mtb* infection during pregnancy raises levels of immune-regulatory cytokines (19),
220 which inhibit the infant's immunological response to vaccinations.

221 The current study also reports decreased Tetanus-specific IgG vaccine titres among cases.
222 Because the vaccine is administered at six weeks (20), there could have been delayed priming of
223 B cells. In addition, since pregnant women are vaccinated with Tetanus toxoid (21), the maternal
224 IgG that crosses the placenta is likely to induce anergy to the infant's immune system, thereby
225 causing a dampened immune response. These findings highlight the need for improved vaccine
226 strategies for infants exposed to TB and a better understanding of vaccine failures in certain
227 populations. The effects of TB exposure are also seen with other vaccines like Diphtheria and
228 Tetanus. With vaccine failure in a certain group of people, efforts need to be taken to identify
229 more shortfalls of the existing vaccines and pave the way for effective vaccines possibly tailored
230 to populations. This will enormously contribute to the End TB strategy.

231 This study further highlights the impact of maternal TB on the birth outcomes of babies,
232 especially low birth weight. Similar results were reported elsewhere (22, 23), affirming this
233 outcome. Vaccination delays associated with low birth weight further hamper the health
234 outcomes of these babies, contributing to lower responses to vaccines and increased vulnerability
235 to infections (24). We postulate that the effects of TB exposure are not only observed with low
236 birth weight. Therefore, when assessing for TB exposure aftereffects, babies with normal weight
237 should not be overlooked. Moreover, the regression analysis revealed that the weight of the

238 babies slightly affected BCG-specific IgG responses, as shown in supplementary figure S1A.
239 Our results also revealed that the mothers to our cases had low haemoglobin concentrations
240 compared to the mothers of the controls. Low haemoglobin during pregnancy is associated with
241 poor neonatal outcomes not limited to preterm births and very low birthweights (25). However,
242 the babies' responses were not affected by their haemoglobin concentrations following the
243 regression analysis, as shown in Supplementary Figure S1B. These findings show an increased
244 risk for these mothers, especially resulting in preterm babies and low-weight babies.

245 **Strengths and limitations**

246 In this study, baby case samples were matched with controls regarding age and gender to control
247 for confounder biases. We report that the study had some limitations. The ATB yield was low,
248 which affected the number of participants studied. However, we were able to demonstrate a
249 statistically supported difference. Some of our participants were enrolled during puerperium, so
250 the babies received the initial vaccines before enrolment. This limited our understanding of the
251 initial status of these babies before vaccination. Also, data on mothers' vaccination status against
252 tetanus during pregnancy was not collected, and we can only anticipate that since it is part of
253 routine antenatal care, they all received this vaccine. We anticipate that this could have further
254 dampened immune responses to the vaccine among cases.

255 **Conclusion**

256 Babies born to mothers with active TB disease: (i) Had low birth weights, (ii) Presented with
257 reduced vaccine-specific IgG responses for BCG and the other infant vaccines in general but
258 markedly at baseline. This could be resulting from persistent *Mycobacterial tuberculosis*
259 antigenemia. We speculate a similar scenario to the *DoHAD* theory. We propose a larger
260 prospective study with longer follow-ups to explore outcomes of vaccination and TB disease

261 risk. This would also answer whether the suppressed response to the vaccine among exposed
262 infants is due to other factors such as the participant's household or environment and nutrition, in
263 addition to revealing whether the responses improve or completely diminish over time. A study
264 on determining the quality of antibodies from active TB mothers, which would look at antibody
265 affinity and avidity to compare these between cases and controls, is necessary. Finally, looking at
266 the transcriptomic changes in the blood of these infants exposed to TB would be insightful. This
267 would inform some of the highly expressed biomarkers potentially used to diagnose childhood
268 TB.

269 **References**

- 270 1. Perumal R, Naidoo K, Padayatchi N. TB epidemiology: where are the young women?
271 Know your tuberculosis epidemic, know your response. *BMC Public Health*. 2018;18(1):417.
- 272 2. K JS, A B, G KH, S MG. Tuberculosis in pregnant women and neonates: A meta-review
273 of current evidence. *Paediatr Respir Rev*. 2020;36:27-32.
- 274 3. Lee JS, Lim CH, Kim E, Lim H, Lee Y, Choung JT, et al. Congenital miliary tuberculosis
275 in an 18-day-old boy. *Korean J Pediatr*. 2016;59(Suppl 1):S64-s7.
- 276 4. Samedi V, Field SK, Al Awad E, Ratcliffe G, Yusuf K. Congenital tuberculosis in an
277 extremely preterm infant conceived after in vitro fertilization: case report. *BMC Pregnancy and*
278 *Childbirth*. 2017;17(1):66.
- 279 5. Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. *Obstet Gynecol*.
280 2020;135(6):1444-53.
- 281 6. Hui SYA, Lao TT. Tuberculosis in pregnancy. *Best Pract Res Clin Obstet Gynaecol*.
282 2022;85(Pt A):34-44.

- 283 7. Thyssen SM, Benn CS, Gomes VF, Rudolf F, Wejse C, Roth A, et al. Neonatal BCG
284 vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort
285 study. *BMJ Open*. 2020;10(2):e035595.
- 286 8. Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskär T, Sommerfelt H, for the P-EBFSG.
287 Child survival and BCG vaccination: a community based prospective cohort study in Uganda.
288 *BMC Public Health*. 2015;15(1):175.
- 289 9. Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, Serubanja J, et al.
290 Maternal Latent Mycobacterium tuberculosis Does Not Affect the Infant Immune Response
291 Following BCG at Birth: An Observational Longitudinal Study in Uganda. *Front Immunol*.
292 2020;11:929.
- 293 10. Mawa PA, Nkurunungi G, Egesa M, Webb EL, Smith SG, Kizindo R, et al. The impact
294 of maternal infection with Mycobacterium tuberculosis on the infant response to bacille
295 Calmette-Guerin immunization. *Philos Trans R Soc Lond B Biol Sci*. 2015;370(1671).
- 296 11. Mansoor N, Scriba TJ, de Kock M, Tameris M, Abel B, Keyser A, et al. HIV-1 infection
297 in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. *J*
298 *Infect Dis*. 2009;199(7):982-90.
- 299 12. Sykes L, MacIntyre DA, Yap XJ, Ponnampalam S, Teoh TG, Bennett PR. Changes in the
300 Th1:Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone
301 prostaglandin 15-deoxy- $\Delta(12,14)$ -prostaglandin J2. *Mediators Inflamm*. 2012;2012:416739.
- 302 13. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal Immunological
303 Adaptation During Normal Pregnancy. *Front Immunol*. 2020;11:575197.
- 304 14. Langel SN, Blasi M, Permar SR. Maternal immune protection against infectious diseases.
305 *Cell Host & Microbe*. 2022;30(5):660-74.

- 306 15. Edwards KM. Maternal antibodies and infant immune responses to vaccines. *Vaccine*.
307 2015;33(47):6469-72.
- 308 16. Nabunya P, Mubeezi R, Awor P. Prevalence of exclusive breastfeeding among mothers
309 in the informal sector, Kampala Uganda. *PLoS One*. 2020;15(9):e0239062.
- 310 17. Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, et al. The
311 Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant
312 Antibody Responses: Individual-Participant Data Meta-Analysis. *Front Immunol*.
313 2021;12:689394.
- 314 18. Soans S, Mihalyi A, Berlaimont V, Kolhapure S, Dash R, Agrawal A. Vaccination in
315 preterm and low birth weight infants in India. *Hum Vaccin Immunother*. 2022;18(1):1-12.
- 316 19. Manjeese W, Mvubu NE, Steyn AJC, Mpfana T. Mycobacterium tuberculosis-Induced
317 Maternal Immune Activation Promotes Autism-Like Phenotype in Infected Mice Offspring. *Int J*
318 *Environ Res Public Health*. 2021;18(9).
- 319 20. Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization.
320 *World Health Stat Q*. 1988;41(2):59-63.
- 321 21. Gupta SD, Keyl PM. Effectiveness of prenatal tetanus toxoid immunization against
322 neonatal tetanus in a rural area in India. *Pediatr Infect Dis J*. 1998;17(4):316-21.
- 323 22. LaCourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of Adverse Infant
324 Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting: A Population-Based
325 Retrospective Cohort Study. *Infect Dis Obstet Gynecol*. 2016;2016:6413713.
- 326 23. Yadav V, Sharma JB, Kriplani A, Bhatla N, Kachhawa G, Mahey R, et al. Obstetrics
327 outcome in pulmonary tuberculosis. *Indian Journal of Tuberculosis*. 2022;69(3):305-10.

328 24. Banu EA, Nechita A, Elkan-Cojocaru EM, Baciuc G, Manole A, Chelaru L. Risk of
329 tuberculosis in low birth weight children from East Romania. Arch Med Sci. 2020;16(1):162-6.

330 25. Zhang Q, Lu X-M, Zhang M, Yang C-Y, Lv S-Y, Li S-F, et al. Adverse effects of iron
331 deficiency anemia on pregnancy outcome and offspring development and intervention of three
332 iron supplements. Scientific Reports. 2021;11(1):1347.

333 **Author contributions**

334 DS performed laboratory experiments, analysed data, and drafted the manuscript. IAB, AN, SC,
335 RN, FB, JBB, PS, APK, DK, and NR participated in the concept development and reviewed the
336 manuscript. PS developed the experimental protocols that followed the experiment and offered
337 technical laboratory training to perform the experiments. IAB sourced funding for the research.

338 **Declaration of conflict of interest**

339 The authors declared no conflict of interest.

340 **Data availability**

341 The authors will make raw data that guided these conclusions available upon request.

342 **Acknowledgement**

343 A vote of special thanks goes to the Tuberculosis and Comorbidities Research Consortium's
344 field team for data collection. We thank the study participants and the health facility
345 administrators for their engagement in this study. This work was supported by the Crick African
346 Network, which receives its funding from the UK's Global Challenges Research Fund
347 (MR/P028071/1), and by the Francis Crick Institute, which receives its core funding from Cancer
348 Research UK (FC1001647), the UK Medical Research Council (FC1001647), and the Wellcome
349 Trust (FC1001647). We also acknowledge HEPI-SHSS for offering a research contribution to

350 the laboratory work. This work was presented at conferences and an abstract of this work was
351 published as a conference paper in BMJ, by the EDCTP Forum, 2023.

352 Tables

353 **Table 1 shows baseline participant characteristics**

Babies	Cases (n=25)	Controls (n=25)	P value
*Weight (Kgs) [median (IQR)]	3.0 (2.1 - 3.2)	3.4 (2.7 - 4.4)	0.03
Age (weeks) [(median (IQR)]	7 (2-12)	12 (1-16)	0.45
Sex (male) (female)	8 12	8 12	>0.99
HIV status (positive) (negative)	7 18	8 13	0.47
Antenatal care (ANC) Postnatal care (PNC)	6 19	4 18	0.63

354

355 *Means a p-value less than 0.05. Missing values for weight, age, sex, haemoglobin
356 concentration, HIV status, and Antenatal versus postnatal care are 11, 12, 10, 10, 4, and 3,
357 respectively.

358 **Table 2: Vaccine responses among cases and control at the different follow-up time points**

359

Type of Vaccine	Mean (IU/mL)	Mean Difference (MD)	95% CI	SE of difference	P-Value
BCG					
Baseline (V0)					
Cases	125.8	-15.37	-29.30 to -1.449	6.727	0.032
Controls	141.1				
Month 3 (V1)					
Cases	122.6	-5.605	-25.77 to 14.56	9.862	0.574
Controls	128.2				
Month 6 (V2)					
Cases	113.6	-6.531	-34.57 to 21.50	13.130	0.626
Controls	120.1				
Month 9 (V3)					
Cases	116.8	17.37	-145.1 to 179.9	42.220	0.717
Controls	99.42				

Tetanus					
V0					
Cases	1.744	-1.173	-1.647 to -	0.226	<0.0001
Controls	2.917		0.6989		
V1					
Cases	1.716	-0.6286	-1.139 to -	0.248	0.018
Controls	2.344		0.1186		
V2					
Cases	1.595	-2.645	-5.890 to 0.5989	1.437	0.098
Controls	4.240				
V3					
Cases	1.713	-0.5535	-10.88 to 9.778	0.912	0.649
Controls	2.267				
Diphtheria					
V0					
Cases	0.042	-0.01935	-0.066 to 0.027	0.022	0.392
Controls	0.062				
V1					
Cases	0.022	-0.05215	-0.08795 to -	0.017	0.0059
Controls	0.075		0.01635		
V2					
Cases	0.045	0.004833	-0.05016 to	0.026	0.8563

Controls	0.040		0.05983		
V3					
Cases	0.063	0.008933	-0.1102 to	0.048	0.8589
Controls	0.054		0.1281		
Measles					
V0					
Cases	1.759	0.1600	-0.8246 to 1.145	0.4768	0.7402
Controls	1.599				
V1					
Cases	1.582	-0.04220	-1.068 to 0.9836	0.5047	0.9339
Controls	1.624				
V2					
Cases	2.702	0.6660	-1.115 to 2.447	0.8439	0.4409
Controls	2.036				
V3					
Cases	2.990	1.230	-3.300 to 5.759	1.757	0.5155
Controls	1.760				

360 **Legends**

361 **Figure 1(A and B).** Plasma was used to perform ELISA using the Human BCG antibody ELISA
362 kit. Two replicates of each sample were used for both case and control samples. The number of
363 samples (n) for cases and controls at V0 was 19/15; at V1, n= 15/15; at V2, n=12/8; and at V3,
364 n=8/3 respectively. Statistical differences were determined using mixed effects analysis and
365 Tukey's multiple comparison tests. Statistical significance was determined at $p < 0.05$ and a 95%
366 confidence level. * Implies a p-value less than 0.05.

367 **Figure 2 (A and B).** Stored plasma was used to perform ELISA using the Human Tetanus
368 Toxoid Antibody IgG (TT-IgG) ELISA Kit. The number of cases versus controls used at each
369 visit was V0=18/17, V1=15/11, V2=11/10, and V3=9/4, respectively. Statistical differences were
370 determined using mixed effects analysis and Tukey's multiple comparison tests. Statistical
371 significance was determined at $p < 0.05$ and a 95% confidence level. * and **** imply a p-value
372 less than 0.05 and 0.0001, respectively. **Figure 2 (C and D).** The plasma was then used to
373 perform ELISA using the Corynebacterium diphtheriae toxin IgG ELISA kit. The number of
374 cases versus controls at V0=20/14, V1=15/15, V2=13/7, and V3=8/4, respectively. Statistical
375 differences were determined using mixed effects analysis and Tukey's multiple comparison tests.
376 Statistical significance was determined at $p < 0.05$ and a 95% confidence level. ** indicate a p-
377 value less than 0.01. **Figure 2 (E and F).** Plasma was used to perform ELISA using the Human
378 Measles virus IgG antibody (MV-Ab-IgG) ELISA Kit. The number of cases versus controls used
379 at V0=20/16, V1=18/12, V2=11/9, and V3=8/5, respectively. Statistical differences were
380 determined using mixed effects analysis and Tukey's multiple comparison tests. Statistical
381 significance was determined at $p < 0.05$ and a 95% confidence level.

382 **Figure 3 (A, B, C, D).** This figure shows a sub-analysis of IgG vaccine-specific responses for
383 babies of low and normal weights. Mann-Whitney U test was used to determine the statistical
384 differences. Data were expressed as median and interquartile ranges. ** indicate a p-value less
385 than 0.01.





